AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ANAVEX LIFE SCIENCES CORP.

Regulatory Filings Jun 9, 2017

Preview not available for this file type.

Download Source File

CORRESP 1 filename1.htm

ANAVEX LIFE SCIENCES CORP. 51 W. 52nd Street, 7th Floor

New York, NY 10019-6163

June 9, 2017

VIA EDGAR

United States Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

Attn: Hillary Daniels

Re:
Request for Acceleration of Registration Statement on Form S-3
File No. 333-218292

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anavex Life Sciences Corp., a Nevada corporation (the “ Company ”), hereby requests acceleration of the effectiveness of its Registration Statement on Form S-3 (File No. 333-218292), filed with the U.S. Securities and Exchange Commission on May 26, 2017, to 4:00PM ET on June 12, 2017 or as soon thereafter as practicable.

Please direct any questions or comments regarding this filing to Clayton Parker, Esq. at (305) 794-6293 of K&L Gates LLP, legal counsel to the Company.

Sincerely,
/s/ Christopher Missling, PhD
Christopher Missling, PhD Chief Executive Officer

Field: Page; Sequence: 1

Field: /Page

Talk to a Data Expert

Have a question? We'll get back to you promptly.